Actively Recruiting
Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
Led by Xiaotong Hou · Updated on 2025-09-25
80
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.
CONDITIONS
Official Title
Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Receiving VA-ECMO or VV-ECMO support after cardiac surgery
- Systemic anticoagulation is deemed necessary by the ECMO treatment team
- Signed informed consent form
You will not qualify if you...
- Presence of other causes of active bleeding considered unsuitable for study participation
- Long-term use of anticoagulants before ECMO initiation
- Prior use of antiplatelet drugs before ECMO initiation
- Severe liver insufficiency
- Diagnosed connective tissue disease
- History of allergy to heparin or nafamostat mesilate
- Pregnancy
- Previous diagnosis of heparin-induced thrombocytopenia
- Expected death within 48 hours
- Receiving extracorporeal cardiopulmonary resuscitation (ECPR)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
X
Xiaotong Hou, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here